Ponatinib (Iclusig, Takeda Oncology) is now now FDA-approved for the treatment of adult patients with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.
More information.
Posted 1/5/2021
From challenging misconceptions about breast cancer to incorporating paramedical tattooing for survivors after reconstruction, gather valuable takeaways from Oncology Issues in observance of Breast Cancer Awareness Month.
